Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy.
Saved in:
| Title: | Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapy. |
|---|---|
| Authors: | Boytz R; National Emerging Infectious Diseases Laboratories, Department of Microbiology, Boston University, Boston, Massachusetts, USA., Słabicki M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA., Ramaswamy S; Department of Microbiology, Boston University, Boston, Massachusetts, USA., Patten JJ; National Emerging Infectious Diseases Laboratories, Department of Microbiology, Boston University, Boston, Massachusetts, USA., Zou C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Meng C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Hurst BL; Institute for Antiviral Research, Utah State University, Logan, Utah, USA., Wang J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Nowak RP; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Yang PL; Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Microbiology, Harvard Medical School, Boston, Massachusetts, USA., Sattler M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Griffin JD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA., Gray NS; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Gummuluru S; Department of Microbiology, Boston University, Boston, Massachusetts, USA., Davey RA; National Emerging Infectious Diseases Laboratories, Department of Microbiology, Boston University, Boston, Massachusetts, USA., Weisberg E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. |
| Source: | Journal of medical virology [J Med Virol] 2023 Jan; Vol. 95 (1), pp. e28157. Date of Electronic Publication: 2022 Sep 28. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9071 (Electronic) Linking ISSN: 01466615 NLM ISO Abbreviation: J Med Virol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1096-9071 |
|---|---|
| DOI: | 10.1002/jmv.28157 |
